Specifications TableSubject area*Psychiatry; Hepatology*More specific subject area*First episode psychosis; NAFLD*Type of data*Tables, text file*How data was acquired*Prospective cohort study, including clinical evaluation.*Data format*Raw and Analyzed*Experimental factors*Effect of cannabis consumption on the incidence of liver steatosis (NAFLD).*Experimental features*Patients diagnosed with a first episode of non-affective psychosis, and being drug-naïves, were included in a prospective cohort (PAFIP). Patients were treated with antipsychotic medication. Clinical, cognitive and physical examinations were carried out prospectively during the 3-years follow-up period.*Data source location*Autonomous region of Cantabria, Spain.*Data accessibility*Data available at the following public data repository:*\
*Repository name: Mendeley Data*\
*Data identification: Crespo Facorro, Benedicto; Vázquez-Bourgon, Javier (2019), "Cannabis use and liver steatosis", Mendeley Data, v1.*\
*Direct URL to data:*<https://doi.org/10.17632/hwn48wt7j6.1>Related research article*Vázquez-Bourgon J, Ortiz-García de la Foz V, Suarez-Pereira I, Iruzubieta P, Arias-Loste MT, Setién-Suero E, Ayesa-Arriola R, Gómez-Revuelta M, Crespo J, Crespo Facorro B. Cannabis consumption and Non-Alcoholic Fatty Liver Disease. A three years longitudinal study in first episode non-affective psychosis patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 95* (2019) 109677. <https://doi.org/10.1016/j.pnpbp.2019.109677>.**Value of the Data**•Cannabis consumption is associated with key clinical and sociodemographic characteristics of the psychosis, such as age of onset, DUP or symptoms severity.•After ruling out a probable confounding effect of alcohol drinking, cannabis was associated with a smaller risk of NAFLD in the first 3 years after psychosis breakout.•Cannabis effect on liver tissue might be through the modulation of weight gain.

1. Data {#sec1}
=======

We present in this article data derived from secondary analyses of a previous study on the relation between cannabis consumption and NAFLD in a Spanish cohort of drug-naïve patients with a first episode of non-affective psychosis \[[@bib1]\]. Raw data has been made accessible through the public data repository "Mendeley Data" at <https://doi.org/10.17632/hwn48wt7j6.1>.

[Table 1](#tbl1){ref-type="table"} describes some of the main clinical and socio-demographic characteristics of the global study sample and of each cannabis groups (consumers and no consumers).Table 1Baseline sociodemographic and clinical characteristics.Table 1Cannabis usersNo cannabis usersTotalStats[a](#tbl1fna){ref-type="table-fn"}Mean (SD)Mean (SD)Mean (SD)*dfFP*Age at admission, years25.2 (6.0)33.7 (9.9)30.4 (9.5)1; 38990.59\< 0.001DUP, months7.3 (10.3)16.3 (36.7)12.8 (29.7)1; 3868.560.004DUI, months18.1 (21.49)26.3 (45.25)23.98 (37.86)1; 3764.220.041SANS-SAPS at inclusion21.4 (7.6)19.6 (7.6)20.3 (7.7)1; 3885.240.023Initial antipsychotic doses [b](#tbl1fnb){ref-type="table-fn"}215.3 (86.4)206.0 (82.8)209.6 (84.2)1; 3891.130.289% (N)% (N)% (N)*NX*^*2*^*P*Sex, males80.0 (120)40.4 (97)55.6 (217)39058.60\< 0.001Education level, secondary or lower58.7 (88)37.5 (90)45.6 (178)39016.67\< 0.001Family socioeconomic status, Not/Low qualified52.0 (78)49.8 (119)50.6 (197)3890.180.375Unmarried88.0 (132)65.0 (156)73.8 (288)39025.28\< 0.001Living with family72.7 (109)74.2 (178)73.6 (287)3900.110.416StudentUnemployed45.3 (68)39.2 (94)41.5 (162)3901.450.136Diagnosis, schizophrenia54.5 (81)50.8 (121)52.2 (202)3874.700.453Hospitalization at inclusion72.0 (108)65.3 (156)67.9 (264)3891.910.101*Drug consumption*Tobacco smoking, yes88.7 (133)37.5 (90)57.2 (223)39098.70\< 0.001Alcohol consumption, yes85.2 (127)29.3 (70)50.8 (197)388114.94\< 0.001Hazardous alcohol consumption, yes [c](#tbl1fnc){ref-type="table-fn"}4.9 (19)2.8 (11)7.7 (30)3880.1520.435*Concomitant treatments*Anticholinergics, baseline4.7 (7)3.3 (8)3.9 (15)3890.4620.336Hypnotics, baseline33.6 (50)28.9 (69)30.7 (119)3880.950.195Benzodiazepines, baseline66.4 (99)58.2 (139)61.3 (238)3882.660.064Antidepressants, baseline1.3 (2)1.7 (4)1.5 (6)3880.070.578Mood stabilizers, baseline0 (0)0.4 (1)0.3 (1)3870.630.615[^1][^2][^3]

[Table 2](#tbl2){ref-type="table"} describes the baseline and 3-years liver function tests differences between groups (cannabis users vs non users), after having excluded those patients with a moderate-severe alcohol consumption.Table 2Baseline and 3-years liver function tests in first episode psychosis, excluding patients with severe alcohol consumption.Table 2Baseline3-yearsCannabis usersNo cannabis usersStats[a](#tbl2fna){ref-type="table-fn"}Cannabis usersNo cannabis usersStats[a](#tbl2fna){ref-type="table-fn"}Mean (SE)Mean (SE)*dfFP*Mean (SE)Mean (SE)*dfFPFLI algorithm factors*BMI (kg/m^2^)21.9 (0.4)24.0 (0.3)1; 34212.585\<0.00124.1 (0.9)27.3 (0.3)1; 33410.0490.002Waist circumference (cm)81.6 (1.7)84.3 (1.1)1; 1801.3460.24778.7 (3.3)91.2 (0.9)1; 20712.912\<0.001Triglycerides83.5 (4.5)79.3 (2.9)1; 2820.5120.47585.3 (11.9)110.9 (3.5)1; 3334.1580.042*Liver laboratory tests*AST23.5 (2.1)27.8 (1.3)1; 3132.3750.12424.3 (1.9)24.4 (0.6)1; 3340.0010.973ALT21.8 (2.9)28.9 (1.9)1; 3353.2050.07426.3 (3.9)29.9 (1.2)1; 3350.7530.386GGT29.2 (4.9)15.7 (3.2)1; 3164.2760.03926.1 (9.4)27.0 (2.8)1; 3340.0080.930AP83.3 (9.6)92.0 (7.2)1; 1230.4170.52066.2 (5.5)65.6 (1.9)1; 1250.0100.920Bilirubin0.71 (0.09)0.80 (0.07)1; 1030.5130.4760.68 (0.09)0.59 (0.03)1; 1220.8630.355Albumin4.54 (0.04)4.54 (0.03)1; 3050.0060.9394.54 (0.05)4.53 (0.01)1; 3220.0390.844*Other laboratory tests*Platelets250.4 (7.9)249.6 (5.1)1; 2670.0050.941252.5 (12.5)243.7 (3.9)1; 3210.4370.509Leptin6.6 (1.1)9.5 (0.7)1; 2643.6800.05610.0 (2.2)14.8 (0.6)1; 3244.2740.040hsCRP0.17 (0.09)0.16 (0.06)1; 1540.0090.9260.14 (0.12)0.29 (0.03)1; 2011.4950.223*Hepatic disease indexes*FLI15.8 (3.5)18.8 (2.2)1; 1530.4320.5127.4 (7.9)38.6 (2.1)1; 20214.169\<0.001FIB-4 score0.69 (0.05)0.68 (0.03)1; 2500.0310.8760.73 (0.05)0.69 (0.01)1; 3180.7380.391NAFDL score−3.54 (0.14)−3.41 (0.09)1; 2420.5080.477−3.35 (0.19)−3.05 (0.06)1; 3112.2770.132[^4][^5]

[Table 3](#tbl3){ref-type="table"} shows the longitudinal differences in liver function tests between groups (cannabis users, discontinuers, non-users), after having excluded those patients with a moderate-severe alcohol consumption.Table 3Longitudinal differences in liver function tests, after 3 years of antipsychotic treatment, excluding patients with severe alcohol consumption.Table 3Cannabis usersDiscontinuersNon-usersStatistics[a](#tbl3fna){ref-type="table-fn"}Mean diff (SE)Mean diff (SE)Mean diff (SE)*dfFPFLI algorithm factors*BMI (kg/m^2^)3.0 (0.7)4.5 (0.4)3.6 (0.2)2; 3312.7910.063Waist circumference (cm)2.4 (2.8)7.3 (1.8)7.2 (1.0)2; 1711.3360.266Triglycerides7.8 (12.2)27.0 (7.5)35.7 (4.4)2; 2722.1180.122*Other liver laboratory tests*AST0.89 (4.03)−0.91 (2.56)−3.34 (1.45)2; 3030.5220.594ALT6.5 (5.7)5.7 (3.5)1.7 (2.1)2; 3250.4990.608GGT7.3 (6.6)7.5 (4.2)7.2 (2.5)2; 3060.0020.998AP−5.4 (16.3)−18.2 (10.3)−30.4 (7.2) (6.5)2; 1210.9020.409Bilirubin−0.26 (0.11)−0.03 (0.08)−0.22 (0.05)2; 982.5560.083Albumin0.001 (0.09)−0.020 (0.05)−0.028 (0.03)2; 2590.0400.961*Other laboratory tests*Platelets−10.3 (11.9)1.2 (7.1)−13.4 (4.2)2; 2541.4730.231Leptin4.6 (2.7)7.1 (1.6)5.4 (0.9)2; 2470.5630.570hsCRP−0.005 (0.22)0.060 (0.12)0.102 (0.07)2; 1450.1150.892*Hepatic disease indexes*FLI−3.7 (6.6)19.6 (4.2)19.8 (2.3)2; 1445.8260.004FIB-4 score0.022 (0.09)−0.035 (0.05)0.047 (0.03)2; 2370.8030.449NAFDL score0.21 (0.23)0.38 (0.15)0.58 (0.08)2; 2241.2740.282[^6][^7]

And [Table 4](#tbl4){ref-type="table"}, presents the clinical impact of cannabis use over the 3 years period, again after having excluded those patients with a moderate-severe alcohol consumption.Table 4Comparison of proportion of subjects with pathological liver functions tests, at baseline and at 3-years in each cannabis consumption group, excluding patients with severe alcohol consumption.Table 43 year follow-upBaseline% differenceNp[a](#tbl4fna){ref-type="table-fn"}% (n)% (n)**AST,** \> **35 UI/L**Continuer6.9 (2)13.8 (4)−6.9290.687Discontinuers9.7 (7)15.3 (11)−5.6720.424Non-users7.8 (16)14.6 (30)−6.82060.044Total8.1 (25)14.7 (45)−6.63070.015**ALT,** \> **40 UI/L**Continuer16.7 (5)10.0 (3)6.7300.625Discontinuers22.0 (18)8.5 (7)13.5820.019Non-users16.6 (36)12.4 (27)4.22170.253Total17.9 (59)11.2 (37)6.73290.013**GGT,** \> **32 UI/L**Continuer10.0 (3)010.030--Discontinuers23.0 (17)6.8 (5)16.2740.002Non-users19.9 (41)10.7 (22)9.22060.001Total19.7 (61)8.7 (27)11.0310\<0.001**Leptin,** \> **10 ng/ml**Continuer10.0 (2)010.020--Discontinuers42.6 (26)13.1 (8)29.561\<0.001Non-users64.5 (109)36.1 (61)28.4169\<0.001Total54.8 (137)27.6 (69)27.2250\<0.001**hsCRP,** \> **0.3 ng/dL**Continuer011.1 (1)−11.19--Discontinuers20.5 (8)7.7 (3)12.8390.125Non-users24.2 (24)7.1 (7)17.3990.001Total21.8 (32)7.5 (11)14.3147\<0.001**FLI,** ≥ **60**Continuer00012--Discontinuers28.1 (9)6.2 (2)21.9320.022Non-users25.0 (25)9.0 (9)16.0100\<0.001Total23.6 (34)7.6 (11)16.0144\<0.001[^8][^9]

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Population description {#sec2.1}
---------------------------

To obtain the present data, we included adult patients presenting a first episode of non-affective psychosis between 2001 and 2015 (full description of inclusion criteria in Pelayo et al., 2008), for whom we had information of cannabis use (yes/no) both at baseline and at 3-years follow-up \[[@bib2]\]. Patients were evaluated at baseline and periodically thereafter until year 3. Anthropometric measures and fasting blood samples for lipid, glycemic and liver determinations, were collected. Main NAFLD and liver fibrosis scores (FLI, FIB-4 and NAFLD fibrosis scores) were calculated accordingly to previous literature \[[@bib3], [@bib4], [@bib5]\]. Cannabis and other drugs were recorded from patients self-reports.

[Table 1](#tbl1){ref-type="table"} shows the main clinical and socio-demographic characteristics of the study sample, and of each consuming groups (cannabis users and no users), at study entry. It also contains the results from the statistical analyses comparing these two groups regarding their clinical and sociodemographic characteristics. Patients reporting cannabis consumption were significantly younger than the non-consumers. They also presented a shorter duration of untreated psychosis, and more severe psychotic symptomatology at study entry. More patients among the cannabis group reported smoking tobacco and drinking alcohol than in the no-cannabis group.

2.2. Secondary analyses excluding patients with moderate-severe alcohol consumption {#sec2.2}
-----------------------------------------------------------------------------------

Due to the well-known deleterious effect of alcohol on liver, and despite being one of the study\'s exclusion criteria presenting an alcohol dependence, we considered appropriate carrying secondary analyses after exclusion of those patients with alcohol consumption qualifying for moderate-severe drinking. For this, moderate-severe alcohol use was defined using the accepted alcohol consumption thresholds for the diagnosis of NAFLD: 140 and 210 g of alcohol per week in women and men, respectively \[[@bib6]\]. [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"} contains the results from the statistical analyses, both cross-sectional and longitudinal, after excluding these patients (n = 40).
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[^1]: Statistical analyses: Un-adjusted analysis of variance (ANOVA) for continuous variables and chi-square test for categorical variables. Abbreviations: DUP: Duration of untreated psychosis. DUI: Duration of untreated illness. SANS: Scale for the Assessment of Negative Symptoms. SAPS: Scale for the Assessment of Positive Symptoms.

[^2]: Equivalent doses of antipsychotic medication following Gardner et al., 2010 criteria.

[^3]: Alcohol consumption thresholds for the diagnosis of NAFLD: 140 and 210 g of alcohol per week in women and men, respectively (Leoni et al., 2018).

[^4]: Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 score; NAFLD, non-alcoholic fatty liver disease fibrosis score.

[^5]: ANCOVA model: parameter was used as the dependent variable, cannabis use was the fixed factor and age, sex, and tobacco and alcohol consumption use were used as covariates.

[^6]: Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 score; NAFLD, non-alcoholic fatty liver disease fibrosis score.

[^7]: ANCOVA model: mean differences after 3 years of treatment were used as dependent variables, evolution of cannabis use was the fixed factor and age, sex, and tobacco and alcohol use trajectories use were applied as covariates.

[^8]: Abbreviations: FLI, fatty liver Index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; hsCRP, high sensitivity C-reactive protein.

[^9]: McNemar test for repeated measures.
